✦ LIBER ✦

Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia

✍ Scribed by Delgado, Livia; Giraudier, Stephane; Ortonne, Nicolas; Zehou, Ouidad; Cordonnier, Catherine; Hulin, Anne; Chosidow, Olivier; Tulliez, Michel; Valeyrie-Allanore, Laurence

Book ID: 122309945
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 67 KB
Volume: 69
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2013.07.025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Second-Generation Tyrosine Kinase Inhibi

Second-Generation Tyrosine Kinase Inhibitors in the Post-Transplant Period in Patients with Chronic Myeloid Leukemia or Philadelphia-Positive Acute Lymphoblastic Leukemia

✍ Klyuchnikov, Evgeny; Schafhausen, Philippe; Kröger, Nicolaus; Brummendorf, 📂 Article 📅 2009 🏛 S. Karger AG 🌐 English ⚖ 136 KB

Front-Line Therapy With Second-Generatio

Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?

✍ Jabbour, E.; Kantarjian, H. M.; O'Brien, S.; Shan, J.; Quintas-Cardama, A.; Garc 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 126 KB

Frequency of ABL gene mutations in chron

Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors

✍ Marcé, Silvia; Zamora, Lurdes; Cabezón, Marta; Xicoy, Blanca; Boqué, Concha; Fer 📂 Article 📅 2013 🏛 Elsevier Science 🌐 Spanish ⚖ 267 KB

The Achievement of a 3-Month Complete Cy

The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure

✍ Jabbour, Elias; Kantarjian, Hagop; Ghanem, Hady; O'Brien, Susan; Quintas-Cardama 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 305 KB

Molecular responses at 3 and 6 months af

Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib

✍ Boquimpani, Carla; Schaffel, Rony; Biasoli, Irene; Bendit, Israel; Spector, Nels 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 715 KB

Cost-Consequence Analysis of a Treatment

Cost-Consequence Analysis of a Treatment Strategy Including Ponatinib Compared to a Treatment Strategy Including Only the 2nd Generation Tyrosine Kinase Inhibitors (2g TKIs), Dasatinib or Nilotinib, in Resistant Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia, in Italy

✍ Chiroli, S.; Furneri, G.; Pane, F. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB